Time to Sell Ultragenyx Pharmaceutical Inc. (RARE) After The Completion of This Double Bottom Pattern?

February 15, 2018 - By Darrin Black

Investors sentiment decreased to 1.19 in Q3 2017. Its down 0.65, from 1.84 in 2017Q2. It dived, as 17 investors sold Ultragenyx Pharmaceutical Inc. shares while 40 reduced holdings. 15 funds opened positions while 53 raised stakes. 39.75 million shares or 1.85% less from 40.50 million shares in 2017Q2 were reported.
Td Asset Management holds 0% or 31,628 shares in its portfolio. Swiss State Bank holds 67,252 shares or 0% of its portfolio. Wellington Mgmt Llp owns 4.99M shares or 0.06% of their US portfolio. Legal General Gp Public Ltd Co holds 0% or 17,925 shares in its portfolio. Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Us Natl Bank De owns 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 3 shares. State Of Wisconsin Invest Board holds 40,445 shares. Nationwide Fund Advsr holds 0.01% or 57,314 shares. Moreover, Citigroup has 0% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Abingworth Llp has invested 1.4% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). The New York-based Tortoise Inv Management Lc has invested 0.02% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Ubs Asset Mngmt Americas accumulated 25,026 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Axa holds 265,408 shares or 0.06% of its portfolio. Moreover, Columbia Wanger Asset Llc has 1.26% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 1.60M shares.

The chart of Ultragenyx Pharmaceutical Inc. (RARE) shows a double bottom with $44.36 target or 8.00 % below today’s $48.22 share price. The 8 months chart pattern indicates high risk for the $2.26 billion company. It was reported on Feb, 15 by Finviz.com. If the $44.36 price target is reached, the company will be worth $180.80 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 1.24% or $0.59 during the last trading session, reaching $48.22. About 300,293 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 6.49% since February 15, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Among 21 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 14 have Buy rating, 1 Sell and 6 Hold. Therefore 67% are positive. Ultragenyx Pharmaceutical Inc had 58 analyst reports since July 27, 2015 according to SRatingsIntel. The rating was downgraded by Jefferies on Thursday, April 6 to “Hold”. Raymond James initiated Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) rating on Tuesday, September 1. Raymond James has “Outperform” rating and $125.0 target. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Sell” rating by Citigroup on Thursday, September 3. The firm has “Buy” rating given on Friday, October 23 by Jefferies. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Buy” rating by Cowen & Co on Monday, December 4. As per Tuesday, September 26, the company rating was maintained by Jefferies. The stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Outperform” rating by Wedbush on Thursday, March 23. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, August 23. SunTrust maintained the shares of RARE in report on Friday, November 3 with “Hold” rating. The firm has “Hold” rating by Barclays Capital given on Wednesday, September 6.

More important recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Globenewswire.com which released: “Ultragenyx Announces Pricing of Public Offering of Common Stock” on January 24, 2018, also Globenewswire.com published article titled: “Ultragenyx Appoints Camille L. Bedrosian, MD as Chief Medical Officer and …”, Seekingalpha.com published: “Ultragenyx Pharmaceutical: Buy The Offering” on January 24, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was released by: Globenewswire.com and their article: “Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 …” with publication date: February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.